BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Section A, individuals will get diverse doses and schedules of oral ABBV-744 tablet to identify safe dosing program. More individuals will likely be enrolled in the determined monotherapy dosign regimen. In Phase B, individuals will acquire oral ruxolitinib and ABBV-744 are going to be supplied as "incorporate-on" therapy. In Segment C, members